
SQZ
Healthcare · Biotechnology & Medical Research · $12.8M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2023
EPS trend, 90 days to now · -22.4% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 2, 2023 | Before the open | -0.60 | -0.57 | +5.0% |
| May 10, 2023 | After the close | -0.54 | -0.60 | -11.1% |
| Mar 22, 2023 | After the close | -0.80 | -0.46 | +42.5% |
| Nov 9, 2022 | After the close | -0.83 | -0.77 | +7.2% |
| Aug 4, 2022 | After the close | -0.77 | -0.78 | -1.3% |
| May 10, 2022 | After the close | -0.71 | -0.75 | -5.6% |
| Mar 16, 2022 | After the close | -0.69 | -0.43 | +37.7% |
| Nov 10, 2021 | After the close | -0.58 | -0.80 | -37.9% |
| Aug 4, 2021 | After the close | -0.58 | -0.68 | -17.2% |
| May 11, 2021 | After the close | -0.69 | -0.59 | +14.5% |
| Mar 18, 2021 | Before the open | -0.73 | -1.07 | -46.6% |
| Oct 29, 2020 | After the close | -1.01 | -7.03 | -596.0% |
| Sep 2, 2020 | Time not confirmed | — |
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or…
| -0.86 |
| — |